摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-methyl-2-<<(2-fluorobenzoyl)amino>methyl>-5-(2'-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepine | 123903-83-3

中文名称
——
中文别名
——
英文名称
1-methyl-2-<<(2-fluorobenzoyl)amino>methyl>-5-(2'-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepine
英文别名
2-Fluoro-N-[5-(2-fluoro-phenyl)-1-methyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-2-ylmethyl]-benzamide;2-fluoro-N-[[5-(2-fluorophenyl)-1-methyl-2,3-dihydro-1,4-benzodiazepin-2-yl]methyl]benzamide
1-methyl-2-<<(2-fluorobenzoyl)amino>methyl>-5-(2'-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepine化学式
CAS
123903-83-3
化学式
C24H21F2N3O
mdl
——
分子量
405.447
InChiKey
YAOQWBSTVZSGGB-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    30
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    44.7
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    1-methyl-2-(aminomethyl)-5-(2'-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepine邻氟苯甲酰氯三乙胺 作用下, 以 四氢呋喃 为溶剂, 以93%的产率得到1-methyl-2-<<(2-fluorobenzoyl)amino>methyl>-5-(2'-fluorophenyl)-2,3-dihydro-1H-1,4-benzodiazepine
    参考文献:
    名称:
    Cholecystokinin-A receptor ligands based on the .kappa.-opioid agonist tifluadom
    摘要:
    Tifluadom, a kappa-opioid agonist and cholecystokinin-A (CCK-A) receptor antagonist, was utilized as a model to prepare a series of 2-(aminomethyl)- and 3-(aminomethyl)-1,4-benzodiazepines. These compounds were tested in vitro as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. All compounds with IC50's less than 100 microM proved to have greater affinity for the CCK-A receptor, with the most potent analogue, 6e, having an IC50 of 0.16 microM. The benzodiazepines described in this study are simultaneously CCK-A and opioid receptor ligands. The ramification of this dichotomy on current concepts of peptide hormone action are discussed. These results further demonstrate the versatility of the benzodiazepine core structure for designing nonpeptide ligands for peptide receptors and the ability to fine-tune the receptor interactions of these benzodiazepines by appropriate structure modifications.
    DOI:
    10.1021/jm00163a069
点击查看最新优质反应信息

文献信息

  • Use of 2-acylaminomethyl-1,4-benzodiazepine derivatives for the production of pharmaceutical compositions and process for the preparation for pharmaceutical compositions
    申请人:Merck & Co., Inc.
    公开号:EP0170024A2
    公开(公告)日:1986-02-05
    Certain 2-acylaminomethyl-1,4-benzodiazepine derivatives, optical isomer thereof, pharmaceutically acceptable salts and quaternary ammonium salts thereof are used for the production of pharmaceutical compositions which antagonize the function of cholecystokinins in humans.
    某些 2-乙酰氨基甲基-1,4-苯并二氮杂卓衍生物、其光学异构体、药学上可接受的盐及其季铵盐可用于生产拮抗人体胆囊收缩素功能的药物组合物。
  • US4684646A
    申请人:——
    公开号:US4684646A
    公开(公告)日:1987-08-04
  • Cholecystokinin-A receptor ligands based on the .kappa.-opioid agonist tifluadom
    作者:Mark G. Bock、Robert M. DiPardo、Ben E. Evans、Kenneth E. Rittle、Willie L. Whitter、Daniel F. Veber、Roger M. Freidinger、Raymond S. L. Chang、T. B. Chen、Victor J. Lotti
    DOI:10.1021/jm00163a069
    日期:1990.1
    Tifluadom, a kappa-opioid agonist and cholecystokinin-A (CCK-A) receptor antagonist, was utilized as a model to prepare a series of 2-(aminomethyl)- and 3-(aminomethyl)-1,4-benzodiazepines. These compounds were tested in vitro as inhibitors of the binding of [125I]CCK to rat pancreas and guinea pig brain receptors. All compounds with IC50's less than 100 microM proved to have greater affinity for the CCK-A receptor, with the most potent analogue, 6e, having an IC50 of 0.16 microM. The benzodiazepines described in this study are simultaneously CCK-A and opioid receptor ligands. The ramification of this dichotomy on current concepts of peptide hormone action are discussed. These results further demonstrate the versatility of the benzodiazepine core structure for designing nonpeptide ligands for peptide receptors and the ability to fine-tune the receptor interactions of these benzodiazepines by appropriate structure modifications.
查看更多